IDO1 and melanoma: Specifically, HLA-A2 positive patients with advanced malignant melanoma were treated biweekly with 150 mg/m2 temozolomide daily for 7 days followed by subcutaneous vaccination with 250μg/250μg of Sur1M2/IDO peptides in 500 μL Montanide solution at day 8.